Form 4 for LLY Lilly (Eli)
Accepted 2025-02-04 00:00:00 ET · period of report 2025-02-01 · accession 0000059478-25-000028 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-04 | 2025-02-01 | LLY | Skovronsky Daniel | EVP, CSO, Pres. LRL, LLY Imm | F - Tax | $811.08 | -4,004 | 122.9K | -3% | -$3.25M |
| D | 2025-02-04 | 2025-02-01 | LLY | Skovronsky Daniel | EVP, CSO, Pres. LRL, LLY Imm | M - OptEx | $0.00 | +8,989 | 126.9K | +8% | $0 |
| D | 2025-02-04 | 2025-02-01 | LLY | Skovronsky Daniel | EVP, CSO, Pres. LRL, LLY Imm | M - OptEx | $0.00 | -8,989 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-01 | F | D | 4,003.64 | $811.08 | 122,888.36 | D | — | — | |
| 2 | Common | Common Stock | 2025-02-01 | M | A | 8,989 | $0.00 | 126,892 | D | — | — | |
| 3 | Derivative | Restricted Stock Unit | 2025-02-01 | M | D | 8,989 | $0.00 | 0 | D | — · 2025-02-01 to 2025-02-01 | 8,989 Common Stock | (F2) Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. |